Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing
John C. Bell(Ottawa Hospital), Jean‐Simon Diallo(University of Ottawa), Harold Atkins(University of Ottawa), Steve H. Thorne(OSE Immunotherapeutics (France)), J. Andrea McCart(Toronto General Hospital), Rebecca C. Auer(Ottawa Hospital), Femina Kanji(Ottawa Hospital), Marianne M. Stanford, Chris W. Brown(Medical College of Wisconsin), Brian D. Lichty(McMaster University Medical Centre), David H. Kirn(Alameda Applied Sciences Corporation (United States)), Theresa Falls(Ottawa Hospital), Kelley A. Parato
Cited by 132
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in wisconsin: a statewide population-based study
|The Journal of Pediatrics|2003|614
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503